Diku Mandavia joins BrainScope as CMO

BrainScope has welcomed a new member to its executive team, having recently hired Diku Mandavia, M.D., as chief medical officer (CMO). With 28 years of emergency medicine experience and 15 years of commercial medical device experience, Mandavia is an expert in the importance of point-of-care triage in emergency medicine.

“Throughout his career Diku has leveraged his experience as a practicing emergency department (ED) physician, knowledge of how to vet innovative technologies, and vision as a medical device CMO to successfully introduce new technologies that transform patient care in the ED,” said Cynthia Ringo, senior partner, DBL Partners. “Head injuries are at near epidemic levels with 4.8 million patients seeking care at America’s emergency rooms each year. A rapid and objective point of care assessment that can aid in ruling out the likelihood of a brain bleed with high accuracy while also assessing concussion and concussion severity is greatly needed. Diku will help accelerate BrainScope’s efforts to make its technology available to more EDs so patients can benefit from fewer head CTs and objective concussion assessments.”

Mandavia served as global chief medical officer of FUJIFILM Sonosite Inc. since 2009 and FUJIFILM Medical USA since 2015. He joined Sonosite as a medical advisor in 2007 and played a pivotal role in establishing point-of-care ultrasound as the new standard of care in the ED and ICU. At Sonosite, he was instrumental in taking a disruptive technology in miniaturized ultrasound and developing new care pathways at the point-of-care. Mandavia led market development efforts focused on the core markets of emergency medicine, critical care and anesthesia that ultimately led to better patient outcomes at a lower cost. He also previously served as CMO for Ceribell, developing novel point of care EEG for the ED and ICU.

Mandavia is a recognized educator and lecturer with more than 100 publications and 200 speaking engagements. He received his medical degree from Memorial University in Canada, completed his residency at LAC+USC Medical Center and is a graduate of the Stanford Graduate School of Business Executive Program. He is also a Diplomate of the American Board of Emergency Medicine and a Fellow of the Royal College of Physicians and Surgeons of Canada.

“I am thrilled to join BrainScope at this point in its progress toward addressing this pressing need,” said Mandavia. “BrainScope is the only FDA-cleared technology that can objectively assess both brain bleeds and concussions in minutes, and that is just a starting point for applying efficient and effective solutions in the ED environment.”

BrainScope’s proprietary system consists of disposable headsets that connect to its handheld device, which acquires, processes, and extracts thousands of brain activity-based physiological parameters characterizing the EEG signal, transforming them into an actionable result through AI-derived algorithms. The true point-of-care BrainScope assessment takes less than 15 minutes from patient preparation to results enabling clinicians to get rapid, objective insights about the likelihood of brain bleeds and concussions. The Concussion Index is the first electrophysiological marker of concussive injury that aids clinicians in the objective assessment of patients at time of injury, and which can be used over time to track recovery and determine readiness to return to activity. Medical Product Outsourcing